Healthcare authorities in Nigeria and Kenya have taken decisive action by removing a batch of Benylin paediatric cough syrup from circulation. The concern arose when it was discovered that the syrup, purportedly manufactured in South Africa, contained an alarming level of diethylene glycol, a toxic chemical with potentially lethal consequences, particularly for children. Diethylene glycol, when ingested, has been associated with severe health complications and even fatalities. The decision to withdraw the product from the market was prompted by laboratory tests conducted on the cough syrup, which revealed the presence of this hazardous substance.
According to reports from Reuters, the National Agency for Food and Drug Administration and Control (NAFDAC) in Nigeria issued a notice detailing the findings of the laboratory analysis. The agency warned that the high level of diethylene glycol in the syrup posed a significant risk to children aged two to 12, for whom the medicine is intended. Symptoms of diethylene glycol poisoning include abdominal pain, vomiting, diarrhea, headaches, and acute kidney injury, all of which can be life-threatening.
The gravity of the situation is underscored by the fact that diethylene glycol has been implicated in numerous deaths across multiple countries, including Cameroon, Gambia, and Uzbekistan, since 2022. This alarming trend has prompted healthcare authorities worldwide to remain vigilant and enforce strict regulations to prevent further incidents of oral medicine poisoning.
In response to these developments, Kenvue, the company responsible for Benylin, has stated that it is conducting its own assessment and collaborating with NAFDAC to investigate the matter further. The company is seeking to verify the authenticity of the sampled product, as well as the testing methodology employed by the regulatory agency. This proactive approach demonstrates the importance of cooperation between pharmaceutical companies and regulatory bodies in ensuring the safety and efficacy of medical products.
In conclusion, the withdrawal of the Benylin cough syrup underscores the critical importance of stringent quality control measures in the pharmaceutical industry. It serves as a stark reminder of the potential dangers posed by contaminated or adulterated medications and the need for robust regulatory oversight to safeguard public health.
